MannKind | MNKD - Gross Profit On Sales

Stock Price
5.79
Daily Change
0.28 4.99%
Monthly
-1.11%
Yearly
2.75%
Q1 Forecast
5.60

MannKind reported $2.1M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Adma Biologics USD 75.63M 8.4M Sep/2025
Dynavax Technologies USD 78.57M 24.17M Jun/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Insmed USD 111.44M 33.36M Sep/2025
MacroGenics USD 61.25M 88.71M Sep/2025
MannKind USD 2.1M 216K Sep/2025
Merck USD 13.42B 431M Sep/2025
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Pfizer USD 3.54B 7.61B Sep/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Xencor USD 21M 22.61M Sep/2025